Immunovant Sector: Pharmaceuticals and biotechnology (autoimmune and immunology therapeutics) HQ: 320 W 37th St., New York, NY Year Founded: 2018 Key Leaders: Eric Venker, MD, PharmD, CEO Number of Employees: 362 Stage: Public Financial Snapshot: $3.83 billion Notable Investors: SG Americas Securities, Roivant Sciences, RTW Investments, and BVF Partners Key Products: Immunovant is developing Batoclimab, an FcRn-targeting monoclonal antibody for autoimmune diseases (MG, TED, Graves disease), which is in Phase 3 registrational trials
GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon)are prescribed for type 2 diabetes management and, in some formulations, for weight management in adults with obesity or overweight with comorbidities
Genetic factors also influence GLP-1 effectiveness
Chemically speaking, it is the attachment of a glycerin molecule to the fatty acid called stearic acid
![Magikarp (35/102) (Shadowless) [Base Set 1st Edition] ARC025-C](https://cdn.shopify.com/s/files/1/0617/9821/9946/files/6fb1c024-786c-4669-8982-a7a44b7d0465.png?v=1741281259)
![Ariados - VMAX Climax [SECRET RARE]](http://www.thriftgoblin.com/cdn/shop/files/ariados-205184-vmax-climax-chr-character-rare-japanese-pokemon-tag-10-gem-mint-9205506.jpg?v=1783703544)
